KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Short-term Investments (2018 - 2025)

Historic Short-term Investments for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Q3 2025 value amounting to $278.6 million.

  • Aurinia Pharmaceuticals' Short-term Investments fell 1058.58% to $278.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.6 million, marking a year-over-year decrease of 1058.58%. This contributed to the annual value of $275.0 million for FY2024, which is 880.96% down from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Short-term Investments is $278.6 million, which was down 1058.58% from $262.1 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Short-term Investments' 5-year high stood at $311.6 million during Q3 2024, with a 5-year trough of $191.7 million in Q1 2021.
  • Moreover, its 5-year median value for Short-term Investments was $272.5 million (2023), whereas its average is $264.5 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Short-term Investments soared by 4930.1% in 2022, and later crashed by 1176.06% in 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Short-term Investments (Quarter) stood at $234.2 million in 2021, then increased by 26.07% to $295.2 million in 2022, then rose by 2.17% to $301.6 million in 2023, then decreased by 8.81% to $275.0 million in 2024, then grew by 1.3% to $278.6 million in 2025.
  • Its Short-term Investments stands at $278.6 million for Q3 2025, versus $262.1 million for Q2 2025 and $246.5 million for Q1 2025.